A Phase 1, Safety, Tolerability and Pharmacokinetic Profile Study of Intravitreous Injections of HB002.1M (a Vascular Endothelial Growth Factor Receptor Decoy) in Subjects With Neovascular Age-Related Macular Degeneration
Phase of Trial: Phase I
Latest Information Update: 10 May 2019
Price : $35 *
At a glance
- Drugs HB00-2M (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Sponsors Huabo Biopharm
- 07 May 2019 Planned End Date changed from 1 Dec 2019 to 1 Jun 2020.
- 07 May 2019 Planned primary completion date changed from 1 Jul 2019 to 1 Dec 2019.
- 31 Aug 2018 Biomarkers information updated